NCT01484678
Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
StatusActive, Not Recruiting
PhaseNot specified
SponsorUniversity of Florida
Primary completion (estimated)
At risk: Primary completion moved 12 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 24 versions: 18 with changes below, 6 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary and study completion pushed from Aug 31, 2026 to Aug 31, 2027 Show 6 more changesShow less
- Eligibility criteria expanded, about 12 words
- Enrollment closed, study ongoing
- Secondary endpoints: details revised at 3 of 3 entries
- Site details revised at 3 of 3 sites
- Collaborators: details revised at 1 of 4 entries
- Publications: details revised at 37 of 38 entries
- Notable Primary and study completion dates: Aug 31, 2025 to Aug 31, 2026v23
- Minor Site contacts updated at 2 of 3 sites
- Publications: 33 to 38
- Minor Publications: 23 to 33v21
- Minor Primary and study completion dates: Aug 2025 to Aug 31, 2025v20
Show 12 earlier versionsHide 12 earlier versions
Notable Eligibility criteria expanded, about 12 wordsv19 Show 6 more changesShow less
- Primary endpoints revised (3)
- Start date: Apr 1, 2021 to Sep 1, 2020
- Secondary endpoints: 4 to 3
- Study description shortened, about 13 words
- Collaborators: 5 to 4
- Publications: 21 to 23
Notable Trial status: Active, Not Recruiting to Recruitingv18 Show 9 more changesShow less
- Enrollment target: 200 to 550
- Primary and study completion dates: Aug 2021 to Aug 2025
- Start date: May 2010 to Apr 1, 2021
- Eligibility criteria expanded, about 49 words
- Primary endpoints: 2 to 3
- Secondary endpoints: 3 to 4
- Study description expanded, about 158 words
- Site details revised at 3 of 3 sites
- Study arms: 2 to 3
- Notable Primary and study completion dates: Apr 2020 to Aug 2021
- Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 3 of 3 sites
- Publications: 11 to 21
- Minor Enrollment target: 185 to 200v13
Notable Trial status: Active, Not Recruiting to Recruitingv9 Show 5 more changesShow less
- Eligibility criteria shortened, about 18 words
- Primary endpoints revised (2)
- Study sites: 4 to 3
- Secondary endpoints revised (3)
- Study description expanded, about 5 words
Notable Primary and study completion dates: Apr 2015 to Apr 2020v8 Show 4 more changesShow less
- Primary endpoints revised (2)
- Enrollment target: 150 to 185
- Secondary endpoints revised (3)
- Publications: 9 to 11
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 4 of 4 sites
- Publications: 7 to 9
- Minor Publications: 6 to 7v6
- Minor Site contacts updated at 1 of 4 sites
- Publications: 4 to 6
- Minor Publications: 3 to 4v4
- Minor Primary completion date: Apr 2015v3
- Minor Site contacts updated at 1 of 4 sitesv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Change from baseline in intramuscular lipid up to 3-10 years
Timeframe: Change in baseline up to 3-10 years
Change from baseline in muscle T2 up to 3 months in DMD
Timeframe: Change in baseline up to 3 months
Correlation between MR measures of intramuscular lipid, functional endpoints and histological markers.
Timeframe: Through study completion, an average of 1 year
Secondary (3)
Change from baseline in muscle T2 up to 5-10 years
Change from baseline in muscle contractile area up to 5-10 years
Change from baseline in muscle T2 at 6 months
Arms and interventions
Age Matched Controls
Age matched non-affected (non-DMD) boys \* This arm is full Age matched non-affected men, matched for men with Becker MD \*Recruiting
Boys/Men with DMD
This group will include ambulatory and non-ambulatory boys/men with Duchenne Muscular Dystrophy ranging from 5-30 years old. \*Recruiting
Adults with Becker MD
This group will include ambulatory and non-ambulatory men with Becker Muscular Dystrophy ranging from 18-62 years old. \* Recruiting
Sites
3 sites in 1 country